Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.

The plasma concentration of micafungin (MCFG) after intravenous infusion of MCFG at 150 or 300 mg/day over 1 hour to 49 patients with hematologic malignancies were determined, and the relationship between the plasma concentrations and the patients' laboratory parameters of liver and kidney function was analyzed. Plasma samples were obtained at the end of the initial administration of MCFG, 5 to 6 hours after the start of the initial administration, immediately before the second dosing, immediately before the fourth dosing, and the end of the fourth dosing. The plasma concentration of MCFG was measured by high performance liquid chromatography. The plasma concentration of MCFG was correlated with the doses of MCFG per kilogram body weight. The peak concentration after the initial administration was 3.8 times higher than the trough level after the initial administration. The steady-state peak and trough levels were 1.4-1.5 times higher than those after the initial administration. There was no correlation between the laboratory parameters of liver/kidney function and the dose-normalized plasma concentration of MCFG. These results suggest that MCFG can be administered safely to patients with liver or kidney dysfunction without adjusting the dose.

Plasma concentration of micafungin in patients with hematologic malignancies.

In 20 patients with hematologic malignancies, we measured the plasma concentration of micafungin (MCFG) by high-performance liquid chromatography after drip infusion of MCFG, at 150 mg/day over a 1-h period, and we analyzed the results in relation to the patients' laboratory parameters of liver and kidney function. Measurement of the plasma concentration was performed at the end of the initial administration of MCFG, 5 to 6 h after the start of the initial administration, immediately before the second dosing, immediately before the fourth dosing, and at the end of the fourth dosing. The plasma concentration of MCFG was correlated with the doses of MCFG per kilogram body weight (P = 0.0008-0.0036). The peak after the initial administration was 2.6 times higher than the trough value after the initial administration. The steady-state trough value was 1.2 times higher than the trough value after the initial administration. There was no correlation between the liver/kidney function parameters and the plasma concentration of MCFG. These results suggest that there was a good correlation between the plasma concentration of MCFG and the dose of MCFG per kilogram body weight, and that MCFG can be administered safely to patients with liver or kidney dysfunction without adjusting the dose.

The measurement technique of human's bio-signals.

A disaster like a big earthquake usually brings many destroyed buildings and many sufferers are generated in the disaster area. In this situation, sometimes a rescue person encounters a second disaster. This is the big problem to rescue sufferers. In order to avoid a second disaster, many kind of rescue robots are being developed. These robots can find sufferers and rescue them. However, they cannot measure the sufferer's condition at the disaster area. If the sufferer's condition becomes clear before rescue, the rescue efficiency will improve. Therefore, we are developing a rescue robot that can measure some vital signs of sufferer and send measured data to the medical doctor who is in safety place. In this paper, we will describe about a developed method that can measure the pulse and the arterial blood oxygen saturation degree (SPO2) by easy way. We think that these methods will be powerful and useful to rescue sufferers.